BioStock: BiBBInstruments kicks off 2022 with capital raise
After reaching a key clinical milestone with EndoDrill Model X in deep tumours of the upper gastrointestinal tract at the end of 2021, BiBBInstruments is looking to expand its clinical programme into both existing and new cancer indications in 2022. In preparations for this, the company has announced raising 21.6 MSEK in a directed share issue. BioStock spoke with BiBB’s CEO Fredrik Lindblad to get his thoughts.
Read the full interview with BiBBInstrument's CEO Fredrik Lindblad at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se